TAMPA, FLA. (PRWEB) JULY 01, 2021 — Psilera Inc., formerly Psilera Bioscience (“Psilera”), a Florida-based biotechnology company specializing in the clinical development of psychedelics and analogues, has secured $2,500,000 in a non-brokered series of seed preferred funding (the “Financing”). The influx of funding was led by Iter Investments with participation from Baird Inc., JLS Fund, Receptor…


Previous articleNavigating Psychedelics for Clinicians and Therapists Course: Informational Meeting with Joe Moore
Next articlePTSF66 – Philosophical Critiques, Legalization Updates, and Inclusive Research